Although ipilimumab is the only antibody therapy to date that has shown significant impact on overall survival in advanced melanoma, ongoing late phase clinical trials are presently exploring anti-CTLA4 antibodies alone or in combination with other antibodies, immunotherapies and chemotherapeutic agents (Tables I and II). Here, CTLA4 is linked to melanoma.